parkinson's disease retatrutide clinical trial A Big Week for GLP-1 Drugs - by Eric Topol Current Therapies in Clinical Trials

These data points help you and your provider make informed decisions about dose adjustments and treatment duration

GLP-1 receptor agonists are large, water-loving peptides, and the skin's outer barrier is built to block exactly those molecules

Although the drugs are still pricey, the costs for some brands have dropped significantly since they were first introduced, says Wood

Purchasing from unregulated sources is unsafe and illegal

Continued Growth in GLP-1 Compounding Despite Regulatory Headwinds Despite the resolution of GLP-1 shortages and increased regulatory scrutiny, compounded prescriptions for semaglutide and tirzepatide continue to rise

Tirzepatide reduced the apnea-hypopnea index by about 25 to 29 events per hour from baselines of roughly 50 events per hour, a reduction of about half, alongside substantial weight loss